香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. | 截 | 至6月30日止六個月 | 2025年 | 2024年 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | （未 | 經 | 審 | 核） | （未 | 經 | 審 | 核） | 人民幣千元 | 附 | 人民幣千元 | 註 | | 收 | 入 | 3,181,110 | 3,074,582 | 4 | 銷售成本 | (1,023,501) | (996,032) | | | | | | 毛 | 利 | 2,157,609 | 2,078,550 | | | | | | | | | | 197,797 | 202,931 | 其他收入及收益 | 銷售及分銷開 ...

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

Group 1 - The core point of the article highlights the recent stock performance of Green Leaf Pharmaceutical, which saw a decline of 2.12% to 3.69 CNY per share with a trading volume of 304 million CNY [1] - Green Leaf Pharmaceutical operates in four major therapeutic areas: oncology, central nervous system, cardiovascular, and digestive and metabolic diseases, with a product portfolio of over 30 products available in more than 80 countries and regions [1] - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1] Group 2 - The company is set to disclose its interim report for the fiscal year 2025 on August 28 [1]

本次交易涉及其他关联方：Ong Tiong Sin、RRJ Capital IV Ltd、RRJ Capital Master Fund IV,L.P.。 香港联交所最新资料显示，8月13日，Kale Asset Holding Ltd减持绿叶制药(02186)1124.6万股，平均每股 作价3.763港元，总金额约为4231.87万港元。减持后最新持股数目约为3亿股，最新持股比例为7.93%。 ...

智通财经APP获悉，香港联交所最新资料显示，8月13日，Kale Asset Holding Ltd减持绿叶制药 (02186)1124.6万股，平均每股作价3.763港元，总金额约为4231.87万港元。减持后最新持股数目约为3亿 股，最新持股比例为7.93%。 本次交易涉及其他关联方：Ong Tiong Sin、RRJ Capital IV Ltd、RRJ Capital Master Fund IV, L.P.。 ...

Group 1 - The top three companies with the highest short positions as of August 15 are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 14.92%, 14.41%, and 13.40% respectively [1][2] - The companies with the largest absolute increase in short positions are Heng Rui Medicine (01276), Yao Cai Securities (01428), and Modern Animal Husbandry (01117), with increases of 2.49%, 1.34%, and 1.31% respectively [1][2] - The companies with the largest absolute decrease in short positions are Ganfeng Lithium (01772), WuXi AppTec (02359), and Fourth Paradigm (06682), with decreases of -2.98%, -2.67%, and -2.28% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Ping An Insurance (02318) at 12.46%, Green Leaf Pharmaceutical (02186) at 12.36%, and Vanke Enterprises (02202) at 12.13% [2] - The companies with the most significant increases in short ratios include Heng Rui Medicine (01276) from 0.51% to 2.99%, Yao Cai Securities (01428) from 3.47% to 4.81%, and Modern Animal Husbandry (01117) from 4.74% to 6.05% [2] - The companies with the most significant decreases in short ratios include Ganfeng Lithium (01772) from 13.32% to 10.34%, WuXi AppTec (02359) from 17.59% to 14.92%, and Fourth Paradigm (06682) from 2.74% to 0.46% [2][3]

Core Viewpoint - Jiangsu Enhua Pharmaceutical Co., Ltd. has had its application for the market launch of Oxycodone Naloxone Extended-Release Tablets accepted, indicating a significant step in the competitive landscape of pain management medications in China [1][3]. Group 1: Product Overview - Oxycodone Naloxone Extended-Release Tablets are a combination of the potent opioid agonist oxycodone and the opioid antagonist naloxone, designed for treating moderate to severe chronic pain that is not effectively managed by non-opioid medications [3][5]. - The total sales of oxycodone in Chinese hospitals reached CNY 165.52 billion, with a projected sales increase of 13.92% to CNY 17.54 billion in 2024, highlighting its dominant position in the moderate to severe pain treatment market [3][5]. Group 2: Market Dynamics - The market for Oxycodone Naloxone Extended-Release Tablets is expected to be substantial, with potential to disrupt the current market structure dominated by NAPP Pharmaceuticals, which holds a 99.44% market share of oxycodone extended-release tablets in China [5][7]. - The first application for this product was submitted by Green Leaf Pharmaceutical in January 2022 but was not approved, indicating the competitive challenges in the market [7][11]. Group 3: Regulatory and Competitive Landscape - The product has been classified as a Category 4 generic drug, with the application officially accepted on August 19, 2025, marking it as the first approved domestic version of Oxycodone Naloxone Extended-Release Tablets [1][9]. - The high technical barriers and complex patent challenges associated with the product have limited the number of domestic generic manufacturers, with the core patent set to expire in August 2027 [12][17]. Group 4: Industry Trends - The increasing focus on high-barrier products and the shift from simple generics to innovative approaches in the extended-release formulation space reflect a deep adjustment in the industry landscape, driven by heightened competition and the need for technological advancements [17].

绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万股。 ...

智通财经APP讯，绿叶制药(02186)发布公告，于2025年8月20日，因转换可转换债券而发行5291.9万 股。 ...

格隆汇8月20日丨绿叶制药(02186.HK)发布公告，2025年8月20日，按每股兑换价港币3.672元兑换由公 司发行的2025年到期的2500万美元5.85%利率可转换债券而发行5291.94万股普通股股份。 ...